News Release
<< Back |
Reata pharmaceuticals, inc. announces first quarter 2017 financial and operating results |
![]() |
Financial Highlights The Company incurred operating expenses of Corporate Highlights As of All outstanding Term Loans will mature on Product Development Highlights Reata is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing product candidates to address rare and life-threatening diseases with few or no approved therapies by targeting molecular pathways that regulate cellular metabolism and inflammation. Our lead product candidates, bardoxolone methyl and omaveloxolone, are members of a class of small molecules that target an important transcription factor, called Nrf2, to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. Bardoxolone Methyl in Pulmonary Arterial Hypertension and Pulmonary Hypertension due to Interstitial Lung Disease Bardoxolone Methyl is currently being studied in a Phase 3 trial, known as CATALYST, for the treatment of pulmonary arterial hypertension associated with connective tissue disease (CTD-PAH), as well as a Phase 2 trial, known as LARIAT, for the treatment of PAH and pulmonary hypertension due to interstitial lung disease (PH-ILD). In Because bardoxolone methyl was active in patients with CTD-PAH, a fibrotic disease, in earlier LARIAT cohorts, we believe that bardoxolone methyl may be effective in PH-ILD patients. We are currently enrolling patients with PH-ILD caused by sarcoidosis, idiopathic pulmonary fibrosis, CTD, and idiopathic interstitial pneumonia in the LARIAT trial in four separate groups in cohort 4. Data have not been presented from cohort 4. We anticipate that data from PH-ILD patients in LARIAT will be available in the second half of 2017. Bardoxolone Methyl in Chronic Kidney Disease Caused by Alport Syndrome Bardoxolone methyl is also currently being studied in a single, pivotal Phase 2/3 trial, known as CARDINAL, for the treatment of chronic kidney disease (CKD) caused by Alport syndrome. Alport syndrome is a rare and serious hereditary disease with no currently approved therapies. Reata has initiated the Phase 2 portion of CARDINAL and enrolled the first patient in We have designed the Phase 3 portion of the trial to support registration and the primary endpoint will be eGFR change as compared to placebo at 48 weeks. The eGFR change at one year will be measured after 48 weeks while the patient is on treatment and after withdrawal of drug for four weeks (retained eGFR). After withdrawal, patients will be restarted on study drug with their original treatment assignments and will continue on study drug for a second year. The eGFR change at two years will be measured also after 100 weeks while the patient is on treatment and after withdrawal of drug for four weeks (retained eGFR). If the trial is successful, the year one retained eGFR data could support accelerated approval under subpart H of the Federal Food, Drug, and Cosmetic Act (the FD&C Act), and the year two retained eGFR data could support full approval under the FD&C Act. Reata expects to have Phase 2 data in the second half of 2017 and to have the Phase 3 one year withdrawal data in the first half of 2019. Omaveloxolone in Rare Neuromuscular Diseases and Immuno-Oncology During the quarter, Reata advanced the clinical development of omaveloxolone, a close analog of bardoxolone methyl that has improved blood-brain barrier penetration. The Company believes that it may benefit patients with various types of neuromuscular diseases because impaired mitochondrial function and chronic inflammation have been shown to be key features of many of these diseases. The Company is initially targeting two rare and serious genetic diseases: Friedreich’s ataxia (FA), and mitochondrial myopathies (MM). Both trials are designed in two parts with the first part being dose-ranging and the second part designed to provide additional efficacy and safety data with the potential to be used to support registration. We are evaluating omaveloxolone in patients with FA in the MOXIe trial. MOXIe is being conducted at sites in We are evaluating omaveloxolone in patients with MM in the MOTOR trial. Part one of the trial focuses on the evaluation of safety and efficacy of omaveloxolone doses ranging from 2.5 mg to 160 mg. Data for multiple endpoints are being collected, with the primary efficacy endpoint being the change in peak work, as measured by exercise testing on a recumbent bicycle. The key secondary endpoint is the change from baseline in patients’ 6MWD. Data from MOTOR part one are expected in the second half of 2017. The Company is also conducting an open-label Phase 1b/2 trial, known as REVEAL, to evaluate the safety, pharmacodynamics, and efficacy of omaveloxolone in combination with existing immunotherapies for the treatment of metastatic melanoma. The Company is using omaveloxolone in combination with checkpoint inhibitors to restore an immune response against the tumor in the presence of so called myeloid derived suppressor cells (MDSCs). MDSCs mask the tumor from the immune system by the production of mitochondrial ROS. Through this approach, Reata hopes to significantly increase the proportion of patients who respond to immunotherapy. Data from REVEAL are expected during the second half of 2017. About Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata’s two most advanced clinical candidates (bardoxolone methyl and omaveloxolone) target the important transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. Forward-Looking Statements This press release includes certain disclosures which contain “forward-looking statements,” including, without limitation, statements regarding the success, cost and timing of our product development activities and clinical trials, our plans to research, develop and commercialize our product candidates, and our ability to obtain and retain regulatory approval of our product candidates. You can identify forward-looking statements because they contain words such as “believes,” “will,” “may,” “aims,” “plans” and “expects.” Forward-looking statements are based on Reata’s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in Reata’s filings with the Contact: |